Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, November 4, 2026

Back to the front page

The Buyback Shows Up (ESRT Q3 2026)

Empire State Realty Trust repurchased $85.8 million of shares at $4.56 each, using 1359 Broadway sale proceeds to fund buybacks and debt reduction.

ESRT $1.3B
Orphan REITs 6 clicks

From X

@calvinblissett

Calvin Blissett on X

I'm sorry it's a pretty bold claim "a better $NVR" I should elaborate. Cury looks like NVR transplanted into a structurally tighter housing market, with even stronger current unit economics. On an apples-to-apples S&P Global methodology, Cury generated 84.2% ROIC in 2025 versus 47.0% for NVR, while Cury's inventory turned 3.77x versus NVR's 3.26x. (https://t.co/pMkkNhSOWD). ROIC is preferable here to ROE or EPS because NVR's enormous buybacks reduce shares and equity and can make per-share growth and ROE look better. The opportunity set is also more extreme: Brazil's official housing deficit is 5.77 million homes, equal to 7.4% of occupied households, while Freddie Mac estimates the U.S. shortage at 3.7 million units against roughly 150.8 million housing units, or ~2.5% of housing stock. FJP Cury then concentrates affordable housing in São Paulo and Rio, precisely where affordability and housing scarcity are most acute because these are the richest cities in Brazil, while using land swaps, customer presales and subsidized MCMV financing to keep remarkably little of its own capital trapped in each project. The result is basically the feature that makes NVR exceptional pushed further: Cury currently turns each real of invested capital substantially harder, while operating against a relative housing shortage several times larger than America's.
@StableBread 1 click

Fajasy on X

My bear, base, and bull cases value Boost Run’s $BRUN stock on year-end 2026 ARR (on the same basis as the multiples of CoreWeave $CRWV, Nebius $NBIS, and $IREN), which $BRUN will report with its Q4 results in March 2027. None of the three cases adds the $160.7M/year from the July order and Cohere, since both start in 2027. The peers’ contracts that start after 2026 aren’t in their year-end ARR either, so they’re priced into the multiples instead. Since the peers’ multiples leave out the debt they’ll take on to reach year-end ARR, I hold $BRUN’s net debt at today’s $244.3M, rather than adding the lease debt from its H2 2026 build. Each case’s value is year-end ARR times the multiple, minus the $244.3M of net debt, divided by the 88.8M fully diluted shares plus any new shares from a stock sale. I start with the $231.4M of ARR from contracts already running, then add (1) the June order’s $69.2M/year if it starts by December 31 and (2) however much of the $99.4M from contracts without disclosed terms is running by then. Bear case ($4.76, -46%) The bear case assumes $BRUN has no new financing to show by its Q3 report, lessors fund 70% of the H2 2026 build instead of 79.5% (below the 72.0% lessors funded in 2025), and the June order’s November 30 start slips into 2027, so 2026 GPU spending stays at the $1.0B low end of management’s range. That implies year-end ARR of $280M, 30% short of the target, a $62.2M stock sale at $8.89/share (7.0M new shares) to cover the funding gap and three months of 2027 payments, and today’s 2.5x, for a value of $4.76/share. I give the bear case about a 20% chance. Base case ($16.17, +82%) The base case assumes $BRUN lands new lease or asset-backed financing by year-end, starts the June order on November 30, and reaches its $400M target without selling stock. That implies $400M of year-end ARR at CoreWeave’s 4.2x, the median of the three peers, for a value of $16.17/share. I use today’s median, since the base case only solves $BRUN’s own financing problem. It assumes no relief on rates or borrowing costs, which would lift the peers’ multiples too. Bull case ($19.78, +122%) The bull case assumes everything in the base case, plus relief on rates and borrowing costs that lifts the peers’ multiples. That implies $400M of year-end ARR at 5.0x, still below Nebius’s 5.9x, for a value of $19.78/share. So the bull case is really a bet on the market, not on anything more from $BRUN. From $8.89/share, you’re risking a $4.13 loss (-46%) in the unlikely bear case for a $10.89 gain (+122%) in the more likely bull case. P.S. These cases use the October 16 close and predate $BRUN’s October 26 release, which says it has closed more than $600M of non-dilutive project financing in 2026.

Investor Letters

All letters

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AA $10BNKE $60B
Aurelion Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

SITC $192MCURB $3.6B
Real Assets, Real Value 5 clicks

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

CPNG $27B
Speedwell Memos 3 clicks

update on Gartner

Gartner’s growth has stalled after federal contract losses and cautious commercial spending, raising questions about its competitive…

IT $13B
scuttleblurb 1 click

Recycle Bin

Used aircraft engines can be repurposed as gas turbines, easing data center power constraints while tightening aviation supply.

EQT $33BRRC $12B
Doomberg 8 clicks
AMRZ · long

Amrize

Amrize (AMRZ) produces aggregates, cement and roofing materials across the US and Canada.

AMRZ $22B
Value Investors Club 3 clicks

TWLO Q3 FY12/26 Earnings Review

Twilio's Q3 revenue rose 20% to $1.56 billion, but Q4 organic growth guidance fell to 11% to 12% and RPO declined 28%.

TWLO $33B
Cestrian Capital Research 3 clicks

Namib Minerals: Research Flash

Namib Minerals accelerates Redwing’s restart, targeting first gold this month and a ramp from 338 ounces monthly to 835 ounces by Q2 2027.

NAMM $46M
Atrium Research - Equity Research 6 clicks

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

STVN $3.6B
Best Anchor Stocks 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.